Bibliography
- Brewer GJ. Treatment of Wilson’s disease: our patients deserve better. Expert Opin Orphan Drug 2014;2(12):1245-810.1517/21678707.2014.975207
- Roberts E, Schilsky M. Diagnosis and treatment of Wilson’s disease an update. Hepatology 2008;47(6):2089-111
- European Association For The Study of The Liver Disease. EASL clinical practice guidelines: Wilson’s disease. J Hepatol 2012;56(3):671-85
- Hoogenraad TU, Koevoet R, De Ruter Korver EG. Oral zinc sulphate as long term treatment in Wilson’s disease (hepatolenticular degeneration). Eur Neurol 1970;18(3):205-11
- Czlonkowska A, Gajda J, Rodo M. Effects of long-term treatment in Wilson’s disease with d-penicillamine and zinc sulphate. J Neurol 1996;243(3):269-73
- Czlonkowska A, Litwin T, Karlinski M, et al. D-penicillamine versus zinc sulfate s first-line therapy for Wilson’s Diseases. Eur J Neurol 2014;21(4):599-606
- Dziezyc K, Karliński M, Litwin T, et al. Compliant treatment with anti-copper agents prevents clinically overt Wilson’s disease in pre-symptomatic patients. Eur J Neurol 2014;21(2):332-7
- Maselbas W, Chabik G, Czlonkowska A. Persistence with treatment in patients with Wilson disease. Neurol Neurochir Pol 2010;44(3):260-3
- Czlonkowska A, Tarnacka B, Litwin T, et al. Wilson’s disease cause of mortality in 164 patients during 1992-2003 observation period. J Neurol 2005;252:698-703
- Brewer G. Penicillamine should not be used as initial therapy in Wilson’s disease. Mov Disord 1999;14(4):551-4
- Brewer GJ, Terry CA, Aisen AM, et al. Worsening of neurologic syndrome in patients with Wilson’s disease with initial penicillamine therapy. Arch Neurol 1987;44(5):490-3
- Stuerenburg HJ. CSF copper concentrations, blood-brain barrier function, and coeruloplasmin synthesis during the treatment of Wilson’s disease. J Neural Transm 2000;107(3):321-9
- Kalita J, Kumar V, Chandra S, et al. Worsening of Wilson disease following penicillamine therapy. Eur Neurol 2014;71(3-4):126-31
- Weiss KH, Thurik F, Gotthardt DN, et al. Efficacy and safety of oral chelators in treatment of patients with Wilson’s disease. Clin Gastroenterol Hepatol 2013;11(8):1028-35
- Weiss KH, Gothardt DN, Klemm D, et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson’s disease. Gastroenterology 2011;140(4):1189-98
- Dzieżyc K, Litwin T, Sobańska A, et al. Symptomatic copper deficiency in three Wilson’s disease patients treated with zinc sulphate. Neurol Neurochir Pol 2014;48(3):214-18
- Walshe JM. Cause of death in Wilson disease. Mov Disord 2007;22(15):2216-20
- Bruha R, Marecek Z, Pospilova L, et al. Long-term follow-up of Wilson disease: natural history, treatment, mutations analysis and phenotypic correlation. Liver Int 2011;31(3):83-91
- Svetel M, Pekmezovic T, Petrovic I, et al. Long-term outcome in serbian patients with Wilson disease. Eur J Neurol 2009;16(7):852-7